Stereotaxis confirms Bill Mills as CEO

– USA, MO – Stereotaxis, Inc. (Nasdaq:STXS) announced today that its board of directors has appointed Chairman William C. Mills III to Chief Executive Officer, effective February 12, 2014. Mr. Mills has been serving as interim CEO since April 2013.

“Stereotaxis is now poised to build on our history of product innovation that can result in major advances in the delivery of patient cardiac therapies,” said Fred A. Middleton, Director. “We believe Bill is the right person to lead these initiatives during the next phase of our Company’s development.”

“As Chairman of Stereotaxis, I am very mindful of our potential as a leading innovator and provider of clinically validated robotic technology in the expanding global market for complex cardiac electrophysiology (EP) procedures, a market that is trending towards automation,” said William Mills, Stereotaxis Board Chairman and Chief Executive Officer. “With the substantial recent progress we have made to strengthen the Company’s financial position, we are increasingly focused on furthering our product innovation to improve patient outcomes, and I am very excited about the growth opportunities that we see ahead.”

Mr. Mills has served on the Stereotaxis Board of Directors since June 2000 and was elected Chairman in May 2012. He has more than 30 years experience as a venture capitalist with an emphasis on science-based medicine and medical technology. Mr. Mills currently serves as a director on a number of venture capital, corporate and advisory boards, in addition to his role with Stereotaxis. He holds graduate degrees in Chemistry and in Management from MIT and an A.B. in Chemistry from Princeton University.

About Stereotaxis

Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. With over 100 patents for use in a hospital’s interventional surgical suite, Stereotaxis helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced collaboration of life-saving information. Stereotaxis’ core Epoch™ Solution includes the Niobe® ES Remote Magnetic Navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management systems and the Vdrive™ Robotic Mechanical Navigation system and consumables.

The core components of Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere. The V-Sono™ ICE catheter manipulator has received U.S. clearance, and the V-Loop™ circular catheter manipulator will soon be submitted for review by the U.S. Food and Drug Administration.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team